On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Q2 2025 Management View Andrew Dudum, CEO, highlighted the platform’s rapid growth, noting, “At the end of the second quarter, we were serving over 2.4 million subscribers on our platform with nearly ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a fortune off the popularity of weight loss injections.

Hims stock crashed late Monday after the obesity kingpin lagged Wall Street's second-quarter sales forecasts, though profit ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

We recently published 10 Big Names Bleed Double Digits. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales ...

Hims & Hers Health, Inc. HIMS stock is trading lower Tuesday after the company reported a second-quarter sales miss on Monday ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

"We're excited to take this moment to really accelerate both the European expansion, but also use this platform as an accelerant as we move into more markets," Hims & Hers CEO Andrew Dudum told ...